Skip to main content
NCBI home page
Infection and Immunity logoLink to Infection and Immunity
. 1988 May;56(5):1162–1166. doi: 10.1128/iai.56.5.1162-1166.1988

Killing of human myelomonocytic leukemia and lymphocytic cell lines by Actinobacillus actinomycetemcomitans leukotoxin.

D L Simpson 1, P Berthold 1, N S Taichman 1
PMCID: PMC259778  PMID: 3258584

Abstract

The purified leukotoxin of Actinobacillus actinomycetemcomitans kills human leukemic cell lines (e.g., HL-60, U937, and KG-1) and human T- and B-cell lines (e.g., JURKAT, MOLT-4, Daudi, and Raji) in a dose- and time-dependent manner. The 50% effective doses for these cell lines are similar to those established for human polymorphonuclear leukocytes and monocytes. In contrast, other human and nonhuman tumor cell lines are not susceptible to the leukotoxin. These human leukemia and lymphoid cell lines will serve as useful model systems with which to study the molecular specificity and mechanism(s) of action of the actinobacillus leukotoxin.

Full text

PDF
1162

Images in this article

1165Image
on p.1165

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bradford M. M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976 May 7;72:248–254. doi: 10.1016/0003-2697(76)90527-3. [DOI] [PubMed] [Google Scholar]
  2. DiRienzo J. M., Tsai C. C., Shenker B. J., Taichman N. S., Lally E. T. Monoclonal antibodies to leukotoxin of Actinobacillus actinomycetemcomitans. Infect Immun. 1985 Jan;47(1):31–36. doi: 10.1128/iai.47.1.31-36.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Eidels L., Proia R. L., Hart D. A. Membrane receptors for bacterial toxins. Microbiol Rev. 1983 Dec;47(4):596–620. doi: 10.1128/mr.47.4.596-620.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Goldmacher V. S., Anderson J., Schulz M. L., Blättler W. A., Lambert J. M. Somatic cell mutants resistant to ricin, diphtheria toxin, and to immunotoxins. J Biol Chem. 1987 Mar 5;262(7):3205–3209. [PubMed] [Google Scholar]
  5. Harris P., Ralph P. Human leukemic models of myelomonocytic development: a review of the HL-60 and U937 cell lines. J Leukoc Biol. 1985 Apr;37(4):407–422. doi: 10.1002/jlb.37.4.407. [DOI] [PubMed] [Google Scholar]
  6. Hozumi M. Established leukemia cell lines: their role in the understanding and control of leukemia proliferation. Crit Rev Oncol Hematol. 1985;3(3):235–277. doi: 10.1016/s1040-8428(85)80028-7. [DOI] [PubMed] [Google Scholar]
  7. McArthur W. P., Tsai C. C., Baehni P. C., Genco R. J., Taichman N. S. Leukotoxic effects of Actinobacillus actinomycetemcomitans. Modulation by serum components. J Periodontal Res. 1981 Mar;16(2):159–170. doi: 10.1111/j.1600-0765.1981.tb00962.x. [DOI] [PubMed] [Google Scholar]
  8. Taichman N. S., Dean R. T., Sanderson C. J. Biochemical and morphological characterization of the killing of human monocytes by a leukotoxin derived from Actinobacillus actinomycetemcomitans. Infect Immun. 1980 Apr;28(1):258–268. doi: 10.1128/iai.28.1.258-268.1980. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Taichman N. S., Simpson D. L., Sakurada S., Cranfield M., DiRienzo J., Slots J. Comparative studies on the biology of Actinobacillus actinomycetemcomitans leukotoxin in primates. Oral Microbiol Immunol. 1987 Sep;2(3):97–104. doi: 10.1111/j.1399-302x.1987.tb00270.x. [DOI] [PubMed] [Google Scholar]
  10. Taichman N. S., Wilton J. M. Leukotoxicity of an extract from Actinobacillus actinomycetemcomitans for human gingival polymorphonuclear leukocytes. Inflammation. 1981 Mar;5(1):1–12. doi: 10.1007/BF00910774. [DOI] [PubMed] [Google Scholar]
  11. Tsai C. C., McArthur W. P., Baehni P. C., Evian C., Genco R. J., Taichman N. S. Serum neutralizing activity against Actinobacillus actinomycetemcomitans leukotoxin in juvenile periodontitis. J Clin Periodontol. 1981 Aug;8(4):338–348. doi: 10.1111/j.1600-051x.1981.tb02043.x. [DOI] [PubMed] [Google Scholar]
  12. Tsai C. C., McArthur W. P., Baehni P. C., Hammond B. F., Taichman N. S. Extraction and partial characterization of a leukotoxin from a plaque-derived Gram-negative microorganism. Infect Immun. 1979 Jul;25(1):427–439. doi: 10.1128/iai.25.1.427-439.1979. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Tsai C. C., Shenker B. J., DiRienzo J. M., Malamud D., Taichman N. S. Extraction and isolation of a leukotoxin from Actinobacillus actinomycetemcomitans with polymyxin B. Infect Immun. 1984 Feb;43(2):700–705. doi: 10.1128/iai.43.2.700-705.1984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Zambon J. J. Actinobacillus actinomycetemcomitans in human periodontal disease. J Clin Periodontol. 1985 Jan;12(1):1–20. doi: 10.1111/j.1600-051x.1985.tb01348.x. [DOI] [PubMed] [Google Scholar]
  15. Zambon J. J., DeLuca C., Slots J., Genco R. J. Studies of leukotoxin from Actinobacillus actinomycetemcomitans using the promyelocytic HL-60 cell line. Infect Immun. 1983 Apr;40(1):205–212. doi: 10.1128/iai.40.1.205-212.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES